Open Access
05.09.2021 | COVID-19 | Original Research
Intravitreal Dexamethasone Implant in Patients Who Did Not Complete Anti-VEGF Loading Dose During the COVID-19 Pandemic: a Retrospective Observational Study
To compare the functional and anatomic outcomes between eyes in patients with diabetic macular edema (DME) who underwent a complete anti-vascular endothelial growth factor (VEGF) loading dose with aflibercept and those who were switched to dexamethasone intravitreal (DEX) implant after an incomplete anti-VEGF treatment regimen during the coronavirus disease 2019 (COVID-19) pandemic.
Methods
This was a retrospective and comparative study conducted on patients with DME. Main outcome measures were mean change in best corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to month 4.
Results
Forty-three eyes (23 eyes in the anti-VEGF group and 20 eyes in the DEX group) were included. Mean BCVA significantly improved from 37.7 ± 25.3 and 35.7 ± 22.0 letters at baseline to 45.4 (23.9) (mean adjusted BCVA improvement 7.6 ± 20.8 letters, p = 0.033) and 46.1 ± 26.0 (mean adjusted BCVA improvement 10.6 ± 15.9 letters, p = 0.049) at month 4 in the anti-VEGF and DEX groups, respectively, with no significant differences between study groups (mean adjusted BCVA difference 2.8 letters, 95% CI − 9.4 to 14.9 letters, p = 0.648). There were no statistically significant differences in the proportion of eyes that achieved a BCVA improvement of ≥ 5, ≥ 10, and ≥ 15 letters between groups. CRT was significantly reduced from baseline to month 4 in both DEX (mean adjusted CRT reduction 167.3 ± 148.2 µm, p = 0.012) and anti-VEGF groups (mean adjusted CRT reduction 109.9 ± 181.9 µm, p < 0.001), with no differences between them (mean adjusted CRT difference 56.1 µm, 95% CI − 46.0 to 158.2 µm, p = 0.273). Of 20 eyes in the DEX group, 16 (80.0%) and 9 (45.0%) eyes achieved a CRT reduction of ≥ 20% from baseline at 2 months and at 4 months, respectively.
Conclusions
Our results seem to suggest that DEX implant can significantly improve both functional and anatomic clinical outcomes in patients who were unable to complete anti-VEGF loading dose during the COVID-19 pandemic.
Key Summary Points
Why carry out this study?
Switching to a sustained released dexamethasone intravitreal (DEX) implant has seemed to be a feasible option in patients with diabetic macular edema who do not adequately respond to intravitreal vascular endothelial growth factor inhibitor (anti-VEGF) injections.
Measures adopted during the coronavirus disease 2019 (COVID-19) pandemic have dramatically disrupted the provision of health care, resulting in deferral of routine ophthalmic procedures.
This study aimed to compare functional and anatomic outcomes in patients with diabetic macular edema who underwent a full anti-VEGF regimen (monthly injection during 5 months) versus those who underwent dexamethasone intravitreal implant after an incomplete anti-VEGF treatment regimen.
What was learned from the study?
DEX implant significantly improved both functional and anatomic outcomes in patients who were unable to complete anti-VEGF loading dose.
DEX implant may be a valuable option for treating patients with DME who have not completed the standard anti-VEGF loading dose regimen.
Introduction
Diabetic macular edema (DME) is the leading cause of vision loss in patients with diabetes [1]. DME is a chronic, multifactorial, and sight-threatening condition that critically impacts on the patient’s quality of life [2, 3]. Many different treatment options are currently available for DME; among these, intravitreal injections of anti-vascular endothelial growth factor inhibitors (VEGF) are considered the first line of treatment in center-involving DME [4]. However, on the basis of large clinical trial results, only 33–45% of patients with DME on anti-VEGF agents showed three lines or more of visual improvement [4‐6], which supports the presence of multiple factors contributing to the pathophysiology of DME [5‐7]. Since there is increasing evidence about the role of inflammation in the pathophysiology of DME, corticosteroids have taken an active role in its treatment [7‐11].
Anzeige
With the coronavirus disease 2019 (COVID-19) outbreak over the last year, the strategies adopted by different governments to reduce the risk of infection spread have dramatically disrupted the provision of health care, resulting in deferral of routine ophthalmic procedures [12, 13]. As a result of the risk of irreversible visual loss, treatment planning and prioritization during the pandemic has become more critical than ever in order to achieve and maintain optimal clinical outcomes in patients with DME [14, 15]. Although we have established specific schedules for patients with DME [16], many patients were unwilling to follow the recommended treatment regimen [16].
Switching from anti-VEGF injections to a sustained released dexamethasone intravitreal (DEX) implant has been shown to provide good functional and anatomic outcomes [17‐20]. Thus, because we have encountered many patients with DME who were unable to comply with the anti-VEGF scheduled treatment regimen, we considered DEX implant as an option for treating these patients during the COVID-19 pandemic.
This study aimed to compare functional and anatomic outcomes in patients with DME who underwent a full anti-VEGF regimen (monthly injection during 5 months) versus those who underwent DEX treatment after an incomplete anti-VEGF treatment regimen.
Methods
This retrospective comparative study included 20 patients with DME who were unable to receive a complete loading regimen of at least five consecutive anti-VEGF injections because of the COVID-19 pandemic and subsequently underwent treatment with DEX implant from April 2020 to January 2021 and 23 patients with DME treated from January 2016 to February 2020 with five monthly intravitreal injections of aflibercept as a control group, at a tertiary level hospital (University of Magna Graecia, Catanzaro, Italy). This study adhered to the tenets of the Declaration of Helsinki and was approved by the local ethics committee of the University of Magna Graecia, Catanzaro, Italy.
Anzeige
Inclusion criteria were age 18 years or older, diagnosis of type 2 diabetes mellitus, HbA1c ≤ 9% (75 mmol/mol), sufficiently clear ocular media, adequate pupillary dilation, fixation to permit high quality optical coherence tomography (OCT) imaging; macular edema defined clinically and by structural spectral domain (SD)-OCT as the presence of central retinal thickness (CRT) of ≥ 250 µm with intra/subretinal fluid and not having received any anti-VEGF treatment before starting the study. Exclusion criteria included concomitant ocular disease that could cause macular edema including choroidal neovascularization, retinal vein occlusion, uveitis and recent intraocular surgery less 6 months prior, and the presence of any retinal disease other than diabetic retinopathy (i.e., hypertensive retinopathy, central serous retinopathy, or macular dystrophies). Both phakic and pseudophakic patients were included in the study. Minimum follow-up was 4 months.
If both eyes were eligible, only one eye (chosen at random) was used for the analysis.
Patients who had been switched from anti-VEGF therapy to DEX implant for any reason other than inability to attend consultation due to COVID restrictions were excluded from the study.
Assessments
Each patient was assessed at baseline (prior to aflibercept injection for the anti-VEGF group and prior to DEX implantation for the DEX group) and 2 and 4 months after both interventions. During each follow-up visit, comprehensive ophthalmologic examination was performed including best corrected visual acuity (BCVA) testing using the standard early treatment diabetic retinopathy study (ETDRS) protocol, slit lamp examination, intraocular pressure (IOP) measurement, and dilated fundus biomicroscopy. Structural SD-OCT (Optovue; Optovue Inc., Fremont, CA, USA) was also performed at every visit. Complications were also assessed in all follow-up visits.
Outcomes
Main outcome measures were change in BCVA and CRT from baseline to month 4.
Secondary outcome measures included incidence of adverse events and proportion of eyes that achieved a CRT reduction of ≥ 20% from baseline to month 4; proportion of eyes achieving a BCVA improvement of ≥ 5, ≥ 10, and ≥ 15 letters; and proportion of eyes losing ≥ 5, ≥ 10, and ≥ 15 letters in BCVA. Anatomic success was defined as a CRT reduction of ≥ 10% from baseline to month 4.
Data Analysis
All statistical analysis was performed using IBM SPSS (version 27.0; IBM, Armonk, New York). For descriptive statistics, number (percentage), mean (standard deviation, SD), mean (95% confidence interval, CI), and median (interquartile range) were used as appropriate.
Data were tested for normal distribution using a Shapiro–Wilk’s test.
Anzeige
A Friedman’s two-way analysis test was used to assess the changes in BCVA and CRT.
Analysis of covariance (ANCOVA) was used to compare changes in BCVA and CRT between study groups. The model included “group” as a factor and age, baseline BCVA, and previous laser photocoagulation as covariates. Poisson regression analysis was used to compare the proportion of patients who achieved a specific BCVA gain or loss. Categorical variables were compared using a Fisher’s exact or chi-squared test as appropriate.
Results
Forty-three eyes were included, 23 (53.5%) eyes in the anti-VEGF group and 20 (46.5%) eyes in the DEX group. Mean age was 63.6 ± 9.3 and 62.3 ± 7.4 years in the in the anti-VEGF and DEX groups, respectively (p = 0.617). Minimum and maximum follow-up were 115 days and 136 days for the DEX group and 113 days and 139 days for the anti-VEGF group.
Table 1 summarizes the main demographic and clinical characteristics of the study population. In the DEX group, mean number of intravitreal anti-VEGF injections was 2.4 ± 0.7. Time between the last anti-VEGF injection and first DEX implant in the switch group was 160.7 ± 102.8 days (range 91.0–218.9 days).
Table 1
Baseline demographic and clinical characteristics
Anti-VEGF group (n = 23)
DEX group (n = 20)
p valuea
Age, years
Mean (SD)
63.6 (9.3)
62.3 (7.4)
0.617c
Sex, n (%)
Women
5 (21.7)
7 (35.0)
0.497
Men
18 (78.3)
13 (65.0)
Number of IVI*, n (%)
1
0 (0.0)
2 (10.0)
< 0.001b
2
0 (0.0)
9 (45.0)
3
0 (0.0)
9 (45.0)
5
23 (100.0)
0 (0.0)
Lens status, n (%)
Phakic
4 (17.4)
6 (30.0)
0.473
Pseudophakic
19 (82.6)
14 (70.0)
Preoperative laser, n (%)
None
13 (56.5)
8 (40.0)
0.478b
PRP
4 (17.4)
6 (30.0)
Macular grid
0 (0.0)
1 (5.0)
Combined**
6 (26.1)
5 (25.0)
Presence of IRF, n (%)
No
6 (26.1)
4 (20.0)
0.728
Yes
17 (73.9)
16 (80.0)
Presence of SRF
No
22 (95.7)
16 (80.0)
0.167
Yes
1 (4.3)
4 (20.0)
PDR, n (%)
Yes
14 (60.9)
12 (60.0)
1.000
No
9 (39.1)
8 (40.0)
BCVA***
Mean (SD)
37.7 (25.3)
35.7 (22.0)
0.785c
CRT
Mean (SD)
560.1 (83.7)
583.6 (129.4)
0.478c
VEGF vascular endothelial grow factor, DEX intravitreal dexamethasone implant, SD standard deviation, IVI intravitreal injections, PRP pan retinal photocoagulation, IRF intraretinal fluid, SRF subretinal fluid, PDR proliferative diabetic retinopathy, BCVA best corrected visual acuity, CRT central retinal thickness
*Aflibercept
**PRP + macular grid
***Letters in the Early Treatment Diabetic Retinopathy Study (ETDRS) charts
aFisher exact test
bChi-squared test
cT test
Anzeige
Mean BCVA significantly improved from 37.7 ± 25.3 and 35.7 ± 22.0 letters at baseline to 45.4 (23.9) (mean adjusted BCVA improvement 7.6 ± 20.8 letters, p = 0.033) and 46.1 ± 26.0 (mean adjusted BCVA improvement 10.6 ± 15.9 letters, p = 0.049) at month 4 in the anti-VEGF and DEX groups, respectively; there were no significant differences between study groups (mean adjusted BCVA difference 2.8 letters, 95% CI − 9.4 to 14.9 letters, p = 0.648) (Fig. 1).
Fig. 1
Mean change in best corrected visual acuity in the anti-VEGF and dexamethasone intravitreal (DEX) implant study groups. The vertical bars represent the 95% confidence interval. Intra-group statistical significance was determined using the Wilcoxon test. Statistical significance between groups was determined using the Mann–Whitney U test. No significant differences were found between groups. *p < 0.05 in both groups as compared to baseline
×
There were no statistically significant differences in the proportion of eyes that achieved a BCVA improvement of ≥ 5, ≥ 10, and ≥ 15 letters between groups (Fig. 2). Similarly, there were no differences in the proportion of eyes losing ≥ 5, ≥ 10 , and ≥ 15 letters (Fig. 2).
Fig. 2
Comparison in the proportion of eyes achieving a best corrected visual acuity (BCVA) improvement of ≥ 5, ≥ 10, and ≥ 15 letters and a BCVA loss of ≥ 5, ≥ 10, and ≥ 15 letters in the dexamethasone intravitreal (DEX) implant and anti-VEGF groups. ns No significant difference
×
In the DEX group, there was a statistically significant reduction in CRT from 583.6 ± 129.4 µm at baseline to 473.7 ± 197.0 µm at month 4 (mean adjusted CRT reduction 167.3 ± 148.2 µm, p = 0.012). Similarly, CRT was significantly reduced in the anti-VEGF group from 560.1 ± 83.7 µm at baseline to 392.7 ± 146.9 µm at month 4 (mean adjusted CRT reduction 109.9 ± 181.9 µm, p < 0.001). There were no differences between groups in mean CRT reduction (mean adjusted CRT difference 56.1 µm, 95% CI − 46.0 to 158.2 µm, p = 0.273) (Fig. 3).
Fig. 3
Mean change in best corrected visual acuity in the anti-VEGF and dexamethasone intravitreal (DEX) implant study groups. The vertical bars represent the 95% confidence interval. Intra-group statistical significance was determined using the Wilcoxon test. Statistical significance between groups was determined using the Mann–Whitney U test. No significant differences were found between groups. *p < 0.05 in both groups as compared to baseline
×
Of 20 eyes in the DEX group, 16 (80.0%) and 9 (45.0%) eyes achieved a CRT reduction of ≥ 20% from baseline at 2 months and at 4 months, respectively. At month 4, anatomic success was achieved in 12 (60.0%) eyes in the DEX group and 16 (69.6%) in the anti-VEGF group (p = 0.515).
Anzeige
Regarding safety, 1 eye (4.3%) developed IOP elevation in the anti-VEGF group and 3 (15.0%) in the DEX group (p = 0.233). In all cases topical medications were effective to manage the IOP. Of the 10 phakic eyes at baseline, only 1 (10.0%) eye of a 68-year-old patient in the DEX group developed visually significant lens opacification throughout the follow-up. Additionally, 1 eye (4.3%) in the anti-VEGF group and 2 eyes (10.0%) in the DEX group experienced a BCVA loss of ≥ 15 letters, (p = 0.482).
Discussion
The results of the current paper have shown that DEX implant may be a valuable option for treating patients with DME who have not completed the standard anti-VEGF loading dose regimen.
COVID-19 has posed a global public health threat due to the severity of its contagion and associated morbidity and mortality [16, 17]. In fact, the volume of outpatient and surgical procedures has significantly decreased during the pandemic [12]. In most ophthalmic centers, provision of care was restricted to urgent or emergency cases [21].
Anti-VEGF intravitreal injections are currently considered the standard of care for patients with DME [4]. However, since unintentional treatment interruptions can result in severe adverse visual sequelae [22, 23], evaluation of alternative longer-term therapy is crucial for achieving optimal clinical outcomes among patients with DME [14]. The positive effect of switching to DEX implant in eyes with persistent DME unresponsive to anti-VEGF therapy has been previously reported [17‐20]. Switching to DEX implant has also been shown to result in better anatomical outcomes over those of continued anti-VEGF therapy [24‐26]. In the current study, the indication for switching was not due to lack of efficacy, but rather the patient’s inability to comply with a routine monthly anti-VEGF therapy.
Although, when comparing to those eyes that underwent the standard anti-VEGF therapeutic regimen, switching to DEX implant did not lead better BCVA improvement or CRT reduction, it is noteworthy that one DEX implant significantly improved both functional and anatomic clinical outcomes in those eyes that did not complete anti-VEGF loading dose.
In the DEX group median BCVA improvement between pre- and post-anti-VEGF therapy was not statistically significant (Hodges–Lehmann median difference 5.0 letters, 95% CI − 0.6 to 9.5 letters, p = 0.097). Nevertheless, there was significant reduction in CRT after anti-VEGF injections (Hodges–Lehmann median difference 117.3 µm, 95% CI 44.0 to 191.0 µm, p = 0.002).
Moreover, after adjustment for age, previous laser, and baseline BCVA, mean BCVA improvement was greater in those eyes that were switched to DEX than in those who underwent anti-VEGF loading dose (mean difference 1.99 letters, 95% CI − 8.85 to 12.83), although such a difference was not statistically significant (p = 0.712). However, the power to detect significant differences with the observed values was 7%. Similarly, after adjustment for age, previous laser, and baseline CRT, there were no significant differences in mean CRT reduction between DEX and anti-VEGF groups (mean difference 62.0, 95% CI − 39.6 to 163.6, p = 0.224); however, as happened with BCVA, our study was underpowered to detect such a difference (24%).
Regarding safety, there were no unexpected adverse events and there were no differences between groups in either incidence of ocular hypertension or cataract/lens opacification or loss of BCVA.
According to the European Society of Retina Specialists (EURETINA) guidelines [4], anti-VEGF treatment should be initiated early on with monthly injections, and in those patients who experience positive anatomic and/or functional outcomes, continuing with monthly injections until visual acuity and/or OCT stability is reached. This raises the question of whether anti-VEGF treatment can be continued or should it be restarted? In any case, this would require monthly visits, which during the pandemic would not be possible. Therefore, having a therapeutic alternative, like DEX implant, which provides good anatomical and functional outcomes in both treatment naïve and anti-VEGF refractory patients with DME may be considered as a valuable alternative [12, 20, 27].
The most important limitations of the current study are its retrospective design and small sample size. Selection bias and confounding factors are inherent to retrospective studies; nevertheless, strict inclusion/exclusion criteria aimed to minimized such issues. Additionally, our small sample size also limits the power of the analysis. In fact, with the observed pooled standard deviation and the number of eyes included in each group, the power to detect a mean BCVA improvement of 5 ETDRS letters or a CRT reduction of 25 µm between DEX and anti-VEGF groups, with an alpha error of 0.05 in a bilateral contrast, would be 14% and 8%, respectively. Therefore, further investigations with a larger number of recruited patients would be needed. It should be mentioned that our study did not evaluate the role of OCT biomarkers, which may provide valuable information about the predictive capacity of DEX response. Different OCT biomarkers, such as disorganization of retinal inner layers [28] or ellipsoid zone integrity [29, 30], may predict anatomic and functional outcomes after treatment with DEX implants. This information may be extremely useful, particularly in these times, when the pandemic limits our consultation capacity and it is crucial for optimizing our resources.
Conclusions
Despite these limitations, the results of our study suggested that DEX implant significantly improved both anatomic and functional outcomes in patients who were unable to receive a complete anti-VEGF therapeutic regime during the COVID-19 pandemic.
Acknowledgements
Funding
The authors wish to acknowledge Allergan, an AbbVie company, for their support with the medical writing and publication fees, including the journal’s Rapid Service Fees. It should be noted that Allergan was not involved in the preparation of the manuscript nor did the company influence in any way the scientific conclusions reached.
Editorial Assistance
Editorial assistance in the preparation of this article was provided by Antonio Martinez (MD) of Ciencia y Deporte Ltd. Support for this assistance was funded by Allergan, an AbbVie company.
Authorship
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Authorship Contributions
Vincenzo Scorcia, Giuseppe Giannaccare, Valentina Gatti, Sabrina Vaccaro, Gabriele Piccoli, Annarita Villi, Mario Damiano Toro, Angeli Christy Yu, Iovino Claudio, Francesca Simonelli, and Adriano Carnevali all made substantial contributions to conception, design, analysis and interpretation of data, contributed to writing the article, provided critical revision of the manuscript, and approved the final version.
Disclosures
Vincenzo Scorcia, Giuseppe Giannaccare, Valentina Gatti, Sabrina Vaccaro, Gabriele Piccoli, Annarita Villi, Mario Damiano Toro, Angeli Christy Yu, Iovino Claudio, and Francesca Simonelli have nothing to declare.
Dr Adriano Carnevali has received a grant from Allergan during the conduct of the study.
Neither honoraria nor payments were made for authorship of this article.
All authors declare no proprietary interest.
Compliance with Ethics Guidelines
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Informed Consent
The study protocol was approved by the REGIONE CALABRIA COMITATO ETICO SEZIONE AREA CENTRO (Protocol. n. 281 del 17 Settembre 2020), which waived the need for Informed consent.
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Intravitreal Dexamethasone Implant in Patients Who Did Not Complete Anti-VEGF Loading Dose During the COVID-19 Pandemic: a Retrospective Observational Study
In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.
Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.
Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.
Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.
Update Innere Medizin
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
